Skip to main content
Top
Published in: Acta Diabetologica 1/2012

01-12-2012 | Original Article

Adiponectin is associated with risk of the metabolic syndrome and insulin resistance in women

Authors: George A. King, Sarah E. Deemer, Dixie L. Thompson

Published in: Acta Diabetologica | Special Issue 1/2012

Login to get access

Abstract

The purpose of this study was to examine insulin resistance, markers of the metabolic syndrome, cardiovascular disease (CVD) risk, and serum adiponectin concentrations in pre-menopausal Hispanic and non-Hispanic White (NHW) women. This cross-sectional study examined 119 pre-menopausal women (76 Hispanic, 45 NHW) for markers of the metabolic syndrome (ATP III criteria), level of insulin resistance (HOMA-IR), CVD risk factors, and serum total adiponectin concentrations. Relationships between variables were assessed using Student’s t-tests, Pearson’s and Spearman’s Rho correlations, and stepwise multiple regression analysis. Hispanic women had significantly lower adiponectin concentrations than NHW women, even after controlling for body fat (%) (P < 0.01). Number of markers of the metabolic syndrome was inversely related to total adiponectin concentration for all women combined and for NHW women (P ≤ 0.04), but not for Hispanic women. Insulin resistance was inversely related to adiponectin for all women and for NHW women (P < 0.01), but not significantly associated in Hispanic women. Adiponectin concentration was not significantly associated with number of CVD risk factors for these women. While adiponectin was associated with markers of metabolic syndrome and insulin resistance for all women of this study and despite lower adiponectin concentrations for Hispanic women than NHW women, the role of adiponectin to these conditions among Hispanics remains unclear. There was no significant association between adiponectin and CVD risk for these women. Future research should focus on understanding mechanisms for up-regulating adiponectin secretion and if ethnicity affects adiponectin gene expression and secretion given the beneficial effects derived from elevated adiponectin levels.
Literature
1.
go back to reference Oh DK, Ciaraldi T, Henry RK (2007) Adiponectin in health and disease. Diabetes Obes Metab 9:282–289PubMedCrossRef Oh DK, Ciaraldi T, Henry RK (2007) Adiponectin in health and disease. Diabetes Obes Metab 9:282–289PubMedCrossRef
2.
go back to reference Havel PJ (2002) Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 13:51–59PubMedCrossRef Havel PJ (2002) Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 13:51–59PubMedCrossRef
3.
go back to reference Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746–26749PubMedCrossRef Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746–26749PubMedCrossRef
5.
go back to reference Heidemann C, Sun Q, vanDam RM, Meigs JB, Zhang C, Tworoger SS, Mantzoros CS, Hu FB (2008) Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 149:307–316PubMed Heidemann C, Sun Q, vanDam RM, Meigs JB, Zhang C, Tworoger SS, Mantzoros CS, Hu FB (2008) Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 149:307–316PubMed
6.
go back to reference Aguilar-Salinas CA, Garcia EG, Robles L, Riano D, Ruiz-Gomez DG, Garcia-Ulloa AC, Melgarejo MA, Zamora M, Guillen-Pineda LE, Mehta R, Canizales-Quinteros S, Luna MTT, Gomez-Perez FJ (2008) High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab 93:4075–4079PubMedCrossRef Aguilar-Salinas CA, Garcia EG, Robles L, Riano D, Ruiz-Gomez DG, Garcia-Ulloa AC, Melgarejo MA, Zamora M, Guillen-Pineda LE, Mehta R, Canizales-Quinteros S, Luna MTT, Gomez-Perez FJ (2008) High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab 93:4075–4079PubMedCrossRef
7.
go back to reference Kim J-Y, Wall Evd, Laplante M, Azzara A, Trujillo ME, Hofman SM, Schraw T, Durand JL, Li H, Li G, Jelicks LA, Mehler MF, Hui DY, Deshaies Y, Shulman GI, Schwartz GJ, Scherer PE (2007) Obesity-associated improvements in metabolic profile though expansion of adipose tissue. J Clin Invest 117:2621–2637PubMedCrossRef Kim J-Y, Wall Evd, Laplante M, Azzara A, Trujillo ME, Hofman SM, Schraw T, Durand JL, Li H, Li G, Jelicks LA, Mehler MF, Hui DY, Deshaies Y, Shulman GI, Schwartz GJ, Scherer PE (2007) Obesity-associated improvements in metabolic profile though expansion of adipose tissue. J Clin Invest 117:2621–2637PubMedCrossRef
8.
go back to reference Hadi HA, Suwaidi JA (2007) Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 3:853–876PubMed Hadi HA, Suwaidi JA (2007) Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 3:853–876PubMed
9.
go back to reference Triggle C (2008) The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes. Timely Top Med Cardiovasc Dis p E3 Triggle C (2008) The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes. Timely Top Med Cardiovasc Dis p E3
10.
go back to reference Giannessi D, Maltinti M, DelRy S (2007) Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. Pharmacol Res 56:459–467PubMedCrossRef Giannessi D, Maltinti M, DelRy S (2007) Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. Pharmacol Res 56:459–467PubMedCrossRef
11.
go back to reference Matsuzawa Y, Funahashi T, Kihara S, Shimomura I (2004) Adiponectin and the metabolic syndrome. Arterioscler Thromb Vasc Biol 24:29–33PubMedCrossRef Matsuzawa Y, Funahashi T, Kihara S, Shimomura I (2004) Adiponectin and the metabolic syndrome. Arterioscler Thromb Vasc Biol 24:29–33PubMedCrossRef
12.
go back to reference CDC (2007) National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. U.S. Department of Health and Human Services, Atlanta CDC (2007) National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. U.S. Department of Health and Human Services, Atlanta
13.
go back to reference American College of Sports Medicine (2006) Preparticipation health screening and risk stratification. In: Whaley MH, Brubaker BH, Otto RM (eds) ACSM’s guidelines for exercise testing and prescription, 7th edn. Lippincott Williams & Wilkins, Baltimore, p 22 American College of Sports Medicine (2006) Preparticipation health screening and risk stratification. In: Whaley MH, Brubaker BH, Otto RM (eds) ACSM’s guidelines for exercise testing and prescription, 7th edn. Lippincott Williams & Wilkins, Baltimore, p 22
14.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment—insulin resistance and beta-cell function from fasting plasma-glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment—insulin resistance and beta-cell function from fasting plasma-glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef
15.
go back to reference Li S, Shin HJ, Ding EL, vanDam RM (2009) Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302:179–188PubMedCrossRef Li S, Shin HJ, Ding EL, vanDam RM (2009) Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302:179–188PubMedCrossRef
16.
go back to reference Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 287:356–359PubMedCrossRef Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 287:356–359PubMedCrossRef
17.
go back to reference Ogden CL, Carroll MD, McDowell MA, Flegal KM (2007) Obesity among adults in the United States—no statistically significant change since 2003–2004. NCHS data brief no 1. National Center for Health Statistics, Hyattsville Ogden CL, Carroll MD, McDowell MA, Flegal KM (2007) Obesity among adults in the United States—no statistically significant change since 2003–2004. NCHS data brief no 1. National Center for Health Statistics, Hyattsville
18.
go back to reference Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA (2001) Hypoadiponecinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935PubMedCrossRef Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA (2001) Hypoadiponecinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935PubMedCrossRef
19.
go back to reference Hulver MH, Saleh O, MacDonald KG, Pories WJ, Barakat HA (2004) Ethnic differences in adiponectin levels. Metabolism 53:1–3PubMedCrossRef Hulver MH, Saleh O, MacDonald KG, Pories WJ, Barakat HA (2004) Ethnic differences in adiponectin levels. Metabolism 53:1–3PubMedCrossRef
20.
go back to reference Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, Crandall J, Marcovina S, Goldstein B, Goldberg R (2008) Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 57:980–986PubMedCrossRef Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, Crandall J, Marcovina S, Goldstein B, Goldberg R (2008) Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 57:980–986PubMedCrossRef
21.
go back to reference Hanley AJG, Bowden D, Wagenknecht LE, Balasubramanyam A, Langfield C, Saad MF, Rotter JI, Guo X, Chen Y-DI, Bryer-Ash M, Norris JM, Haffner SM (2007) Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African Americans. J Clin Endocrinol Metab 92:2665–2671PubMedCrossRef Hanley AJG, Bowden D, Wagenknecht LE, Balasubramanyam A, Langfield C, Saad MF, Rotter JI, Guo X, Chen Y-DI, Bryer-Ash M, Norris JM, Haffner SM (2007) Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African Americans. J Clin Endocrinol Metab 92:2665–2671PubMedCrossRef
22.
go back to reference Grundy SM (2004) Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 89:2595–2600PubMedCrossRef Grundy SM (2004) Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 89:2595–2600PubMedCrossRef
23.
go back to reference Reilly MP, Rader DJ (2003) The metabolic syndrome: more than the sum of its parts? Circulation 108:1546–1551PubMedCrossRef Reilly MP, Rader DJ (2003) The metabolic syndrome: more than the sum of its parts? Circulation 108:1546–1551PubMedCrossRef
25.
26.
go back to reference Iwashima Y, Horio T, Kumada M, Suzuki Y, Kihara S, Rakugi H, Kawano Y, Funahashi T, Ogihara T (2006) Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol 98:1603–1608PubMedCrossRef Iwashima Y, Horio T, Kumada M, Suzuki Y, Kihara S, Rakugi H, Kawano Y, Funahashi T, Ogihara T (2006) Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol 98:1603–1608PubMedCrossRef
27.
go back to reference Laughlin GA, Barrett-Connor E, May S, Langenberg C (2007) Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo Study. Am J Epidemiol 165:164–174PubMedCrossRef Laughlin GA, Barrett-Connor E, May S, Langenberg C (2007) Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo Study. Am J Epidemiol 165:164–174PubMedCrossRef
28.
go back to reference Lu G, Chiem A, Anuurad E, Havel PJ, Pearson TA, Ormsby B, Berglund L (2007) Adiponectin levels are associated with coronary artery disease across Caucasian and African-American ethnicity. Trans Res 149:317–323CrossRef Lu G, Chiem A, Anuurad E, Havel PJ, Pearson TA, Ormsby B, Berglund L (2007) Adiponectin levels are associated with coronary artery disease across Caucasian and African-American ethnicity. Trans Res 149:317–323CrossRef
29.
go back to reference Rathmann W, Haastert B, Herder C, Hauner H, Koenig W, Meisinger C, Holle R, Giani G (2007) Differential association of adiponectin with cardiovascular risk markers in men and women? The KORA survey 2000. Int J Obes 31:770–776 Rathmann W, Haastert B, Herder C, Hauner H, Koenig W, Meisinger C, Holle R, Giani G (2007) Differential association of adiponectin with cardiovascular risk markers in men and women? The KORA survey 2000. Int J Obes 31:770–776
30.
go back to reference Wildman RP, Mancuso P, Wang C, Kim M, Scherer PE, Sowers MR (2008) Adipocytokine and ghrelin levels in relation to cardiovascular disease risk factors in women at midlife: longitudinal associations. Int J Obes 32:740–748CrossRef Wildman RP, Mancuso P, Wang C, Kim M, Scherer PE, Sowers MR (2008) Adipocytokine and ghrelin levels in relation to cardiovascular disease risk factors in women at midlife: longitudinal associations. Int J Obes 32:740–748CrossRef
31.
go back to reference Rothenbacher D, Brenner H, März W, Koenig W (2005) Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 26:1640–1646PubMedCrossRef Rothenbacher D, Brenner H, März W, Koenig W (2005) Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 26:1640–1646PubMedCrossRef
32.
go back to reference Lindsay RS, Resnick HE, Zhu J, Tun ML, Howard BV, Zhang Y, Yeh J, Best LG (2005) Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 25:e15–e16PubMedCrossRef Lindsay RS, Resnick HE, Zhu J, Tun ML, Howard BV, Zhang Y, Yeh J, Best LG (2005) Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 25:e15–e16PubMedCrossRef
33.
go back to reference Lawlor DA, Smith GD, Ebrahim S, Thompson C, Sattar N (2005) Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 90:5677–5683PubMedCrossRef Lawlor DA, Smith GD, Ebrahim S, Thompson C, Sattar N (2005) Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 90:5677–5683PubMedCrossRef
34.
35.
go back to reference Patterson N, Hattangadi N, Lane B, Lohmueller KE, Hafler DA, Oksenberg JR, Hauser SL, Smith MW, O’Brien SJ, Altshuler D, Daly MJ, Reich D (2004) Methods for high-density admixture mapping of disease genes. Am J Hum Genet 74:979–1000PubMedCrossRef Patterson N, Hattangadi N, Lane B, Lohmueller KE, Hafler DA, Oksenberg JR, Hauser SL, Smith MW, O’Brien SJ, Altshuler D, Daly MJ, Reich D (2004) Methods for high-density admixture mapping of disease genes. Am J Hum Genet 74:979–1000PubMedCrossRef
Metadata
Title
Adiponectin is associated with risk of the metabolic syndrome and insulin resistance in women
Authors
George A. King
Sarah E. Deemer
Dixie L. Thompson
Publication date
01-12-2012
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue Special Issue 1/2012
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-010-0192-6

Other articles of this Special Issue 1/2012

Acta Diabetologica 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine